Geron Drug Patent Portfolio
Geron owns 1 orange book drug protected by 6 US patents Given below is the list of Geron's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12171778 | Methods of treating myelodysplastic syndrome | 16 Jun, 2039 | Active |
| US12442000 | Use Of Telomerase Inhibitors For The Treatment Of Myeloproliferative Disorders And Myeloproliferative Neoplasms | 15 Mar, 2033 | Active |
| US9375485 | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms | 15 Mar, 2033 | Active |
| US7494982 | Modified oligonucleotides for telomerase inhibition | 27 Dec, 2026 | Active |
| US9388415 | Modified oligonucleotides for telomerase inhibition | 09 Sep, 2026 | Expired |
| US9388416 | Modified oligonucleotides for telomerase inhibition | 09 Sep, 2026 | Expired |
Latest Legal Activities on Geron's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Geron.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 13 Feb, 2026 | US9375485 |
| transaction for FDA Determination of Regulatory Review Period | 13 Feb, 2026 | US9388416 |
| transaction for FDA Determination of Regulatory Review Period | 13 Feb, 2026 | US7494982 |
| transaction for FDA Determination of Regulatory Review Period | 13 Feb, 2026 | US9388415 |
| transaction for FDA Determination of Regulatory Review Period | 21 Nov, 2025 | US9388415 |
| transaction for FDA Determination of Regulatory Review Period | 21 Nov, 2025 | US9388416 |
| transaction for FDA Determination of Regulatory Review Period | 21 Nov, 2025 | US7494982 |
| transaction for FDA Determination of Regulatory Review Period | 21 Nov, 2025 | US9375485 |
| Interim Patent Term Extension Granted | 13 Nov, 2025 | US7494982 |
| Email Notification | 29 Oct, 2025 | US12442000 |
| Mail Miscellaneous Communication to Applicant | 29 Oct, 2025 | US12442000 |
| Miscellaneous Communication to Applicant - No Action Count | 28 Oct, 2025 | US12442000 |
| Recordation of Patent Grant Mailed | 21 Oct, 2025 | US12442000 |
| Patent eGrant Notification | 14 Oct, 2025 | US12442000 |
| Recordation of Patent eGrant | 14 Oct, 2025 | US12442000 |
Geron's Family Patents
Clinical Trials
Recent Clinical Trials by Geron:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis | Geron Corporation | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE1 |
| Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma | Geron Corporation | NA |
COMPLETED
(Jun 1, 2026)
| PHASE2 |
| A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment | Geron Corporation | NA |
ACTIVE NOT RECRUITING
(Jun 1, 2026)
| PHASE3 |
Geron Drug List
Given below is the complete list of Geron's drugs and the patents protecting them.
1. Rytelo
Rytelo is protected by 6 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12171778 | Methods of treating myelodysplastic syndrome |
16 Jun, 2039
(12 years from now)
| Active |
| US12442000 | Use Of Telomerase Inhibitors For The Treatment Of Myeloproliferative Disorders And Myeloproliferative Neoplasms |
15 Mar, 2033
(6 years from now)
| Active |
| US9375485 | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
15 Mar, 2033
(6 years from now)
| Active |
| US7494982 | Modified oligonucleotides for telomerase inhibition |
27 Dec, 2026
(2 months from now)
| Active |
| US9388415 | Modified oligonucleotides for telomerase inhibition |
09 Sep, 2026
(24 days ago)
| Expired |
| US9388416 | Modified oligonucleotides for telomerase inhibition |
09 Sep, 2026
(24 days ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rytelo's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List